Becton, Dickinson and Company $BDX Stock: Third View Private Wealth LLC Cuts Holdings

Third View Private Wealth LLC reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 13.4% in the third quarter, HoldingsChannel.com reports. The firm owned 22,922 shares of the medical instruments supplier’s stock after selling 3,561 shares during the period. Third View Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $4,103,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. TD Waterhouse Canada Inc. increased its stake in Becton, Dickinson and Company by 17.1% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier’s stock valued at $14,715,000 after buying an additional 14,077 shares during the last quarter. Northside Capital Management LLC boosted its stake in shares of Becton, Dickinson and Company by 18.3% in the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock worth $9,280,000 after buying an additional 9,494 shares during the last quarter. NewEdge Advisors LLC boosted its stake in shares of Becton, Dickinson and Company by 35.0% in the 1st quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier’s stock worth $6,923,000 after buying an additional 11,414 shares during the last quarter. Beverly Hills Private Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the second quarter valued at approximately $3,353,000. Finally, Capital Analysts LLC grew its holdings in shares of Becton, Dickinson and Company by 7.5% in the second quarter. Capital Analysts LLC now owns 83,601 shares of the medical instruments supplier’s stock valued at $12,651,000 after acquiring an additional 5,828 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on BDX. Wells Fargo & Company increased their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Barclays assumed coverage on Becton, Dickinson and Company in a research report on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 price objective on the stock. Bank of America raised their target price on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Monday, August 31st. Stifel Nicolaus set a $195.00 target price on Becton, Dickinson and Company in a research report on Friday, August 7th. Finally, Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $185.07.

Becton, Dickinson and Company Trading Down 0.4%

Shares of Becton, Dickinson and Company stock opened at $197.88 on Wednesday. The stock has a market capitalization of $54.52 billion, a P/E ratio of 59.60, a P/E/G ratio of 13.39 and a beta of 0.22. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $200.47. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock’s 50-day simple moving average is $186.86 and its 200 day simple moving average is $170.20.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the business earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Insider Activity at Becton, Dickinson and Company

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. This represents a 3.63% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 6,907 shares of company stock worth $1,269,128. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.